Chemokine blockade as a therapy for renal disease.
Chemokine blockade as a therapy for renal disease.
复制标题
趋化因子阻断作为肾脏疾病的治疗方法。
DOI：
10.1097/00041552-200005000-00004
复制
发表时间：
2000
影响因子：
3.2
通讯作者：
Rovin,BH
中科院分区：
文献类型：
--
作者：
Rovin,BH
趋化因子已通过抗趋化因子抗体、趋化因子受体拮抗剂或靶向趋化因子基因破坏被证实是实验性肾炎的炎症介质。在人类疾病中，趋化因子在肾脏中表达与炎症浸润有关。因此趋化因子阻断是一种潜在的治疗炎症性肾脏疾病的新方法。几种抗趋化因子策略正在开发中。有效地使用抗趋化因子治疗肾脏疾病将需要精确理解单个趋化因子在肾脏病理中的独特作用，以及调节趋化因子表达的遗传因素。
Chemokines have been verified as inflammatory mediators of experimental nephritis by using anti-chemokine antibodies, chemokine receptor antagonists or targeted chemokine gene disruption. In human disease, chemokines are expressed in the kidney in association with inflammatory infiltrates. Chemokine blockade is thus a potentially novel approach to therapy of inflammatory renal disease. Several anti-chemokine strategies are under development. Effective use of anti-chemokine therapy for renal disease will require a precise understanding of the unique roles that individual chemokines have in renal pathology, and the genetic factors that regulate chemokine expression.